Certificate in Psychedelic-Assisted Therapies™ · Mind Medicine Australia
mma-logo-mono
Train for the future of healthcare

Certificate in
Psychedelic-Assisted Therapies
CPATTM

For Medical, Mental Health and
Allied Health Professionals in Australia

“The most rounded professional development I can remember doing - I felt nourished in mind, soul and body.”

Ria, Psychiatrist

“In my 30 years of work as a psychologist, I have never attended such an engaging and informative course of this calibre.”

Maurizio, Psychotherapist

About the Course

Psychedelic-assisted therapies (PAT) are delivered by treatment teams with three main roles: prescriber, primary therapist and secondary therapist. This course has been developed to address the training needs for the three roles, recognising the desirability of members of PAT teams to understand the entire PAT treatment process and the roles each assumes. The Certificate in Psychedelic-Assisted Therapy course provides appropriately qualified and experienced healthcare professionals with the necessary capabilities, knowledge and skills to safely and successfully facilitate PAT in a clinical environment, in accordance with their role as prescriber, or primary or secondary therapist.

Please note: Psychiatrists are responsible for prescribing psychedelic medicines. However, they work as part of a multidisciplinary team including other mental health professionals to deliver treatment. This world-class training program is suitable for both prescribers and therapists.

Prescribers: For those who have the necessary qualifications to prescribe psychedelic medicines, this course will equip them with the knowledge and skills to create and document a PAT treatment protocol, and safely prescribe specific psychedelic medicines for specific mental health conditions.

Therapists: The course will prepare appropriately qualified and experienced healthcare professionals with the skills and knowledge necessary to safely and effectively support patients undergoing PAT as primary or secondary therapists. Note that the ability to practice as a primary therapist in PAT is also dependent on prior relevant clinical experience in psychotherapy.

Training focuses on evidence-based, standardised approaches to PAT that may be integrated with clinicians’ existing psychotherapeutic experience and clinical practice. The course includes a combination of face-to-face and online learning and self-study. It is delivered over 13 weeks of online learning and a 6-day full-time, face-to-face residential workshop. The main psychedelic medicines this course focuses on are MDMA, psilocybin and ketamine.

Training of prescribers and therapists occurs together, reflective of the holistic team approach that characterises PAT. In previous iterations of the course, learners have given positive feedback specifically about the value of training together. However, whilst the curriculum is the same for all learners enrolled, in recognition of the unique roles and levels of responsibility of prescribers and therapists, assessment tasks differ for prescribers and therapists and serve to differentiate the CPAT award into two distinct awards: the CPAT-Prescriber and the CPAT-Therapist. Only psychiatrists and medical practitioners will be eligible to complete the assessment for Prescribers and be awarded the CPAT-Prescriber. The awards of CPAT-Prescriber and CPAT-Therapist are dependent on successful completion of all assessment items.

The Faculty

Dr Gita Vaid (USA) profile picture

Dr Gita Vaid (USA)

Dr Gabor Maté CM (Canada) profile picture

Dr Gabor Maté CM (Canada)

Dr Eli Kotler (AUS) profile picture

Dr Eli Kotler (AUS)

Dr Bessel van der Kolk (USA) profile picture

Dr Bessel van der Kolk (USA)

Dr Lauren Macdonald (UK) profile picture

Dr Lauren Macdonald (UK)

Rabbi Tirzah Firestone (USA) profile picture

Rabbi Tirzah Firestone (USA)

Professor David Nutt (UK) profile picture

Professor David Nutt (UK)

Dr James Fadiman (USA) profile picture

Dr James Fadiman (USA)

Dr Rick Doblin (USA) profile picture

Dr Rick Doblin (USA)

Dr William (Bill) Richards (USA) profile picture

Dr William (Bill) Richards (USA)

Dr David Erritzoe (UK) profile picture

Dr David Erritzoe (UK)

Dr Philip Wolfson (USA) profile picture

Dr Philip Wolfson (USA)

Licia Sky (USA) profile picture

Licia Sky (USA)

Bianca King (Switzerland) profile picture

Bianca King (Switzerland)

Professor Arthur Christopoulos (AUS) profile picture

Professor Arthur Christopoulos (AUS)

Dr Julia King Olivier (Switzerland) profile picture

Dr Julia King Olivier (Switzerland)

Dr David E. Nichols (USA) profile picture

Dr David E. Nichols (USA)

Jeff Leifer (USA) profile picture

Jeff Leifer (USA)

Sara Reed (USA) profile picture

Sara Reed (USA)

Dr Janelle Trees (AUS) profile picture

Dr Janelle Trees (AUS)

Namae Ntumae (USA) profile picture

Namae Ntumae (USA)

Dr Ashleigh Murphy-Beiner (UK) profile picture

Dr Ashleigh Murphy-Beiner (UK)

Francoise Bourzat (USA) profile picture

Francoise Bourzat (USA)

Tania De Jong AM profile picture

Tania De Jong AM

Barry Walker (USA) profile picture

Barry Walker (USA)

Peter Hunt AM profile picture

Peter Hunt AM

Dr Gita Vaid (USA) profile picture

Dr Gita Vaid (USA)

MD

Dr Gita Vaid MD is CPAT’s International Course Director.

Dr Gita Vaid is a Board Certified Psychiatrist and psychoanalyst practicing in New York City. Dr Vaid completed her residency training at NYU Medical Center and her psychoanalytic training at the Institute for Psychoanalytic Education affiliated with NYU. Her early biological and research background includes a completed fellowship in clinical psychopharmacology and neurophysiology at New York Medical College and a research fellowship at NYU Medical Center.

Dr Vaid is currently on faculty and teaches at both IPE and the NYU department of Psychiatry. She has a special interest in teaching interview technique, psychoanalytic theory and British object relations.

Dr Vaid’s current focus and expertise are in psychedelic-assisted psychotherapy. She is a MAPS trained psychedelic therapist and was part of the NY site Phase 3 MDMA psychotherapy study for PTSD.

Dr Vaid is a leader in ketamine assisted psychotherapy which she practices and teaches in New York City.  She serves as a lead instructor at The Ketamine Training Center with psychedelic psychotherapy pioneer, Dr. Phil Wolfson. She is a co-founder of the Center for Natural Intelligence, a multidisciplinary laboratory dedicated to psychedelic psychotherapy innovation and research. She serves as the Director of Psychedelic Awareness and Consciousness research at The Chopra Foundation and with Dr. Deepak Chopra is currently developing protocols integrating meditation with ketamine assisted psychotherapy.

Current publications include:

Vaid G, Walker B. “Psychedelic Psychotherapy: Building Wholeness Through Connection”. Glob Adv Health Med. 2022 Feb 23;11
Gita Vaid, MD, “Psychoanalysis and Psychedelic Psychotherapy : A New Modern Synthesis?” The Wounds of Our Mother Psychoanalysis – New Models for a Psychoanalysis in Crisis.

Dr Gabor Maté CM (Canada) profile picture

Dr Gabor Maté CM (Canada)

BA, MD, Doctor of Laws (honoris causa)

Gabor Maté (pronounced GAH-bor MAH-tay) is a retired physician who, after 20 years of family practice and palliative care experience, worked for over a decade in Vancouver’s Downtown East Side with patients challenged by drug addiction and mental illness. The bestselling author of five books published in nearly 40 languages, including the award-winning In the Realm of Hungry Ghosts: Close Encounters With Addiction, Gabor is an internationally renowned speaker highly sought after for his expertise on addiction, trauma, childhood development, and the relationship of stress and illness. For his ground-breaking medical work and writing he has been awarded the Order of Canada, his country’s highest civilian distinction, and the Civic Merit Award from his hometown, Vancouver. His most recent book, The Myth of Normal: Trauma, Illness and Healing in a Toxic Culture is a New York Times and international bestseller.

Dr Eli Kotler (AUS) profile picture

Dr Eli Kotler (AUS)

MBBS MPM FRANZCP Cert. Old Age Psych. AFRACMA

Dr Eli Kotler is CPAT’s Australian Course Director.

Dr Eli Kotler is a Consultant Psychiatrist and Psychodynamic Psychotherapist. He is the Medical Director of Malvern Private Hospital, an addiction and trauma hospital in Melbourne. Eli completed the inaugural Mind Medicine Australia Certificate in Psychedelic-Assisted Therapies (CPAT)™ course, and has since been on its Faculty.

As a psychiatric trainee, Eli was awarded the Royal College of Psychiatrists Trainee Prize for his Scholarly Project on Depression, as well as a Research Committee Trainee award for his work on Philosophy of Mind. As an adjunct lecturer at Monash University, he oversees medical students on their addiction medicine rotation. He has been invited as a keynote speaker to several conferences and meetings to discuss addictions, trauma and psychedelics. Eli sits on the Committee of the ANZMHA to help organise their yearly addiction conference. He also sits on the inaugural Clinical Advisory Group for the Victorian Responsible Gambling Foundation. Eli is an Associate Fellow of the Royal Australasian College of Medical Administrators, and is a member of the Australasian Professional Society on Alcohol and other Drugs. He also has extensive research experience with novel therapeutics for neurodegenerative diseases.

Due to his interest in trauma, Eli has been appointed an Independent Medical Examiner by WorkSafe Victoria. He has been appointed by the Minister for Workplace Safety to sit on the Victorian Medical Panels, and is an expert witness in historical abuse cases.

Clinically, Eli works in a psychodynamic framework, and attempts to help his patients find freedom from their addictions and trauma through relational experiences, and experiential self-awareness. He is part of the AFL Player’s Association referral network for addiction issues, and his interests in depth-psychology and neuroscience led him to found the Melbourne Neuropsychoanalytic Group. Eli is a Board Director of Mind Medicine Australia.

Dr Bessel van der Kolk MD, Professor of Psychiatry, Boston University School of Medicine and President, Trauma Research Foundation, has spent his career studying how children and adults adapt to traumatic experiences, and have tried to translate emerging findings from pharmacology, neuroscience and attachment research to develop and study potentially effective treatments for traumatic stress in children and adults.

In 1984, Dr van der Kolk set up one of the first clinical/research centers in the US dedicated to study and treatment of traumatic stress in civilian populations, which has trained numerous researchers and clinicians specializing in the study and treatment of traumatic stress, and which has been continually funded to research the impact of traumatic stress and effective treatment interventions. He conducted the first studies on the effects of SSRIs on PTSD; he was a member of the first neuroimaging team to investigate how trauma changes brain processes, and he did the first research linking BPD and deliberate self-injury to trauma and neglect in early childhood.

Currently, Dr van der Kolk is Principal Investigator of the Boston arm of the MAPS 1 and 2 studies on the effects of MDMA on people with chronic PTSD. His seminal book The Body keeps the Score , has been on the New York Times best seller list for over 230 weeks, and has been translated into 42 different languages.

Dr Lauren Macdonald (UK) profile picture

Dr Lauren Macdonald (UK)

BMBS, BSc, PGCert

Dr Lauren Macdonald is one of CPAT’s Residential Facilitators.

She is a psychiatry doctor, psychedelic therapy guide and group facilitator. For the last few years she has been a clinical trial doctor at The Centre for Psychedelic Research (Imperial College London) investigating psilocybin-assisted therapy for anorexia-nervosa, chronic pain, and treatment-resistant depression.

Alongside her clinical roles Lauren regularly facilitates psilocybin retreats in The Netherlands, and is co-founder of Essence Medicine, an organisation providing psycho-spiritual group support to people facing life threatening illness. Lauren is also passionate about educating future psychedelic facilitators and delivers integrative, experiential and heart-centred training for Mind Medicine (Australia) and PsyEdu (UK).

Lauren has trained in medicine, psychology, MDMA-assisted therapy, and yoga, and continues to be a student of earth-based, indigenous wisdom traditions. She is driven to help people come home to themselves, unfold more of who they truly are, and deepen into the beauty and mystery of life.

Rabbi Tirzah Firestone (USA) profile picture

Rabbi Tirzah Firestone (USA)

PhD

Rabbi Tirzah Firestone, Ph.D., is an author, Jungian psychotherapist, a leader in the international Jewish Renewal Movement, and a renowned Jewish scholar and teacher. Widely known for her groundbreaking work on Kabbalah, depth psychology, and the re-integration of the feminine wisdom tradition within Judaism, Rabbi Tirzah lectures and teaches internationally about spiritual and ancient wisdom practices that are honed to assist us at this critical time in world history.

Her latest work, Wounds into Wisdom: Healing Intergenerational Jewish Trauma (Monkfish, 2019) is the recipient of the 2020 Nautilus Book Award Gold in Psychology and the Jewish Women’s Caucus of the Association for Women in Psychology 2020 book award.

Professor David Nutt (UK) profile picture

Professor David Nutt (UK)

BA, MB BChir, MRCP, MA, DM, MRC Psych, FRCPsych, FMedSci, FRCP, FSB

Professor David Nutt is a renowned researcher, policy advisor and author, who is currently Head of Neuropsychopharmacology at Imperial College London.

Under the leadership of Professor Nutt, the Psychedelic Research Group at Imperial College is one of the world’s foremost psychedelic research laboratories, publishing landmark research on psychedelic therapies and neuroimaging studies of the psychedelic state.

Professor Nutt has also held many leadership positions in both UK and European academic, scientific and clinical organisations, including presidencies of: the European Brain Council, the British Neuroscience Association, the British Association of Psychopharmacology, the European College of Neuropsychopharmacology.

He was previously Chair of the UK Advisory Council on the Misuse of Drugs.

Dr James Fadiman (USA) profile picture

Dr James Fadiman (USA)

BA, Ph.D

Dr James Fadiman B.A. (Harvard) M.A., Ph.D. (Stanford) began his  personal psychedelic research a few weeks before starting his graduate work at Stanford where he did his dissertation on the effectiveness of LSD-assisted therapy.  During the research lull of 40 years, he has held a variety of teaching (San Francisco State, Brandeis, and Stanford) consulting, training, counseling and editorial positions. He has taught in psychology departments, design engineering, and for three decades, at the Institute of Transpersonal Psychology (now Sofia University) that he co-founded.

James has published textbooks, professional books, a self-help book, a novel, and a series of videos, Drugs: the children are choosing for National Public Television. His books have been published in 8 languages. He has been the subject of a one-hour documentary released by Page3 Films, featured in a National Geographic documentary and had three solo shows of his nature photography.

James had his own consulting firm and sat on two non-profit boards as well as having been the president of several small natural resource companies. He has been involved in researching psychedelic for spiritual, therapeutic and creative uses and is known for his pioneering work on microdosing .  He has published The Psychedelic Explorer’s Guide: Safe, Therapeutic, and Sacred Journeys, and most recently, Your Symphony of Selves: Discover and Understand More of Who You Are. The book he is writing now has the working title All About Microdosing.

Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master’s thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary’s Concord Prison Experiment. Rick studied with Dr Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife and empty rooms from three children who are all in college or recently graduated.

Dr William (Bill) Richards (USA) profile picture

Dr William (Bill) Richards (USA)

PH.D

Dr William A. Richards (Bill), author of Sacred Knowledge: Psychedelics and Religious Experiences,  is Director of Therapy at Sunstone Therapies in Rockville, Maryland (USA), currently focused on the implementation of psychedelic-assisted therapy in palliative care.

Bill also is a psychologist at the Johns Hopkins Center for Psychedelic and Consciousness Research in Baltimore, where he and his colleagues have been pursuing research with psilocybin since 1999, and teaches at the California Institute of Integral Studies and for MMA’s Certificate in Psychedelic-Assisted Therapies. Bill’s graduate degrees encompass the psychology of religion, theology,  comparative religion and clinical psychology.

Bill’s involvement with psychedelic research originated in Germany at the University of Göttingen in 1963.  From 1967 to 1977, he pursued research with LSD, DPT, MDA and psilocybin at the Maryland Psychiatric Research Center.

Dr David Erritzoe (UK) profile picture

Dr David Erritzoe (UK)

MD, PhD, MRCPsych

Dr. David Erritzoe is a psychiatrist and neuroscientist. He holds a Clinical Senior Lectureship (i.e. Assistant Professorship)  in General Psychiatry in the Centres for Neuropsychopharmacology and Psychedelic Research at Imperial College London and CNWL Mental Health NHS Foundation Trust. Following training in neuroreceptor PET imaging at Columbia University in New York in 2002/03, he undertook a PhD at University Hospital Rigshospitalet in Copenhagen. Since moving to Imperial College in 2009 he has been conductingand overseeing clinical and neuroimaging trials (using PET, MRI, and EEG) into affective disorders and addiction. David is the Clinical Director of Imperial’s Centre for Psychedelic Research. Since early 2021 he has also headed up a new NHS-based research clinic at St Charles Hospital, the CIPPRes Clinic. He is topic lead in Psychiatry at Imperial College London’s Medical School, whilst also lecturing in MSc and BSc neuroscience programs. He has authored more than 110 peer-reviewed scientific papers and 4 book chapters.

Dr Philip Wolfson (USA) profile picture

Dr Philip Wolfson (USA)

MD

Dr Philip Wolfson MD is Principal Investigator for the MAPS sponsored Phase 2, FDA approved 18-person study of MDMA Assisted Psychotherapy for individuals with significant anxiety due to life threatening illnesses. His clinical practice with ketamine has informed his leadership role in the development of Ketamine Assisted Psychotherapy. Phil’s book The Ketamine Papers has been published by MAPS and is the seminal work in the burgeoning ketamine arena. Phil is a sixties activist, psychiatrist/psychotherapist, writer, practicing Buddhist and psychonaut who has lived in the Bay Area for 38 years. He is the author of Noe – A Father/Son Song of Love, Life, Illness and Death (2011, North Atlantic Books).

In the 1980s, he participated in clinical research with MDMA (Ecstasy). He has been awarded five patents for unique herbal medicines. He is a journalist and author of numerous articles on politics, transformation, psychedelics, consciousness and spirit, and was a founding member of the Heffter Research Institute. Phil has taught in the graduate psychology programs at JFK University, CIIS and the UCSF School of Medicine Department of Psychiatry.

Licia Sky (USA) profile picture

Licia Sky (USA)

BFA, LMT

Licia Sky is co-founder of the Trauma Research Foundation.

She is a somatic educator, artist, singer-songwriter, and bodyworker who works with traumatized individuals and trains mental health professionals to use mindful meditation in movement, theater exercises, writing, and voice as tools for attunement, healing, and connection. She is a regular instructor in trauma healing workshops at Cape Cod Institute, Kripalu, and Esalen. For the past decade, she has been teaching expanded awareness in workshops to clinicians and laypeople around the world.

Bianca King (Switzerland) profile picture

Bianca King (Switzerland)

M.A.

Bianca King M.A. is a qualified and experienced Psychological Counsellor and Meditation Teacher, practicing in Geneva, Switzerland. She is co-founder with psychiatrist Dr. Julia King Olivier of the Compassionate Care Center where they carry out Psychedelic Assisted Therapy (PAT) sessions. Bianca is a qualified MAPS MDMA therapist and graduate of the CIIS CPTR training. She has been prominent in the Geneva community for running mindfulness courses for the public, the UN, and International organizations.

Throughout her life, Bianca connected with the practice of vipassana meditation and travelled to Asia to participate in teachings and retreats. She found she was learning about a dimension of the human experience that complimented her education and training in psychotherapy and psychology. For her Masters in Psychotherapy and Counselling through the University of Wales, Bianca concentrated on existential issues as she found her heart was in the work of hospice and palliative care that she had originally experienced at the Petrea King Quest for Life Foundation.

Professor Arthur Christopoulos (AUS) profile picture

Professor Arthur Christopoulos (AUS)

BPharm, PH.D, FAA, FAHMS

Arthur Christopoulos is Professor of Analytical Pharmacology, Dean of the Faculty of Pharmacy & Pharmaceutical Sciences, and Director of the Neuromedicines Discovery Centre, Monash University, Parkville, Australia. Prior to his appointment as Dean, he was a Senior Principal Research Fellow of the NHMRC. His work focuses on novel paradigms of drug action at G protein-coupled receptors, the largest drug-target class for current medicines, and has been applied to fundamental and translational studies encompassing neurological and psychiatric disorders, cardiovascular disease, obesity, diabetes and chronic pain.

Professor Christopoulos has over 340 publications, including in leading journals such as Nature, Science and Cell. He has also been the recipient of multiple major national and international awards. Since 2014-present, Clarivate Analytics have named him a Highly Cited Researcher in Pharmacology and Toxicology, and in 2021 also named him a Highly Cited Researcher in Biology & Biochemistry. In 2017, he was elected a Fellow of the Australian Academy of Health and Medical Sciences and in 2021 was elected a Fellow of the Australian Academy of Science.

Dr Julia King Olivier (Switzerland) profile picture

Dr Julia King Olivier (Switzerland)

MD

After obtaining her MD degree in 2000 at the University of Geneva medical school, Julia completed four years of residency training in Internal Medicine at the University Hospital of Geneva, before opting to specialize in Psychiatry. In 2010 and 2015 she earned her Swiss FMH certifications respectively for Adult Psychiatry and Psychotherapy and also for Adolescent/ Child Psychiatry and Psychotherapy. Julia uses an integrative approach drawing from a wide range of psychotherapeutic models in her practice (Freudian psychodynamic theory, Compassion Focused Therapy, EMDR and Mindfulness approaches). She also facilitates two-part ecopsychiatry workshops in natural settings, combining Shinrin Yoku (Japanese forest bathing) with Breathwork.

In 2021 she earned a Certificate in Psychedelic Assisted Therapy and Research from the California Institute of Integral Studies, and co-founded the Compassionate Care Center in Geneva Switzerland with her colleague and co-therapist Bianca King. The center provides innovative and legal psychedelic assisted therapy to Swiss residents who meet the compassionate use criteria of the Swiss Department of Public Health. She completed the five-part certification in MDMA assisted psychotherapy in 2022. Julia’s current plans involve completing the Consultancy Training to become a MAPS PBC trained Consultant and provide support to new MDMA-assisted therapy practitioners. Julia joined the Fluence training team in 2022 and co-wrote and co-facilitates a humanities focused course entitled “Poetry, symbol, story for psychedelic assisted therapy”.

Dr David E. Nichols (USA) profile picture

Dr David E. Nichols (USA)

BSc, PH.D

Dr David E. Nichols, PhD is an Adjunct Professor of Chemical Biology and Medicinal Chemistry at the University of North Carolina, Chapel Hill.  Previously he held the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology and was a Distinguished Professor of Medicinal Chemistry and Molecular Pharmacology at the Purdue University College of Pharmacy.  He received his B.S. degree in chemistry from the University of Cincinnati in 1969, and the PhD in Medicinal Chemistry from the University of Iowa in 1973, following which he did postdoctoral work in pharmacology at the University of Iowa, College of Medicine.  In 2004 he was named the Irwin H. Page Lecturer by the International Society for Serotonin Research and in 2006 he received the first Provost’s Outstanding Graduate Mentor award from Purdue University.  He has published more than 300 scientific articles, most of which deal with the relationship between molecular structure and biological action.

Jeff Leifer is an impact advisor and educator in the Psychedelic Medicine space. He is the founder of Circadian, a cross-sector collaboration and experience lab building engaged, resilient communities and presenting powerful voices in the fields of innovative mental health and the study of consciousness.

Jeff co-founded the Psychedelic Research, Education and Policy (PREP) funding program at the Threshold Foundation and currently serves on the board of directors for the Ketamine Research Foundation, focused on psychedelic-assisted therapies for depression, PTSD and end of life support. Jeff also serves on the advisory board for Anuma, exploring digital group therapeutics that combine virtual reality (VR) with the science of psychedelics.

Jeff leads the Psychedelic Listening Project, which documents diverse views on the state of the psychedelic ecosystem to inform best practices for philanthropists. The project will inform stakeholders looking beyond traditional funding approaches, prioritizing models that encourage human flourishing and shared decision-making.

Jeff has also worked extensively with Indigenous communities in the Global South to support the embodiment of plant medicine lineage, traditional ecological knowledge and forest-based, economic resiliency.

Prior to launching Circadian, Jeff thrived in the world of social finance, pioneering capital reforms, collaborative governance and public finance accountability. Jeff has an MBA from Yale University and BA from the University of California at San Diego.

Sara Reed (USA) profile picture

Sara Reed (USA)

MS LMFT

Sara Reed is a mental health futurist and Licensed Marriage and Family Therapist. She has spent her early career examining ways culture informs how we diagnose and treat mental illnesses. Sara has participated as a study therapist and participant in psychedelic therapy research and is currently the lead study therapist at Imperial College London for their psilocybin for OCD trial. She lectures on topics fusing culturally sensitive practices within psychedelic-assisted therapy and advises organizations on anti-oppressive and inclusive practices.

Dr Janelle Trees (AUS) profile picture

Dr Janelle Trees (AUS)

FRACGP, MBBS (Hons), BSc (Hons 1), DipAppSc (Acup), CPAT

Dr. Trees, a Goori (Dhanggati) woman and GP, is a dedicated healthcare professional, often serving as the sole doctor in remote areas of Western Australia and the Northern Territory, particularly within Aboriginal communities and islands. With over thirty years of experience, she teaches locally and internationally, specialising in Indigenous health and cultures, emphasizing the importance of Indigenous knowledge for humanity’s future. Dr. Trees initially trained in Traditional Chinese Medicine as an acupuncturist before pursuing science.

An advocate for LGBTQ+ rights at the United Nations, she played a role in founding organisations like the Australian Indigenous Doctors Association (AIDA). As the first Indigenous Honours graduate from the University of Sydney School of Medicine, Dr. Trees continues to champion Indigenous values within educational systems. Beyond her medical career, she excels as an award-winning novelist in Magical Realism and Speculative Fiction.

Namae Ntumae (USA) profile picture

Namae Ntumae (USA)

Namae has been exploring altered states of consciousness and working with plants, herbs, fungi, shamanic breathwork and experiential spiritually transformative modalities for over 30 years. Namae’s approach to awakening is rooted in safety, presence, spontaneity, adaptation, and love. Her innovative and feminine approach combines ancient spiritual practices, indigenous and mystical lineages with therapeutic counseling, tantric embodiment, artistic expressions, scientific knowledge, neurobiology, biomimicry, and ecology. She has created tools of deep transformation, shamanic ceremonies, and rituals that help people connect, love, and attain awareness in altered states, supporting their integration and to adapt  to subtle and dynamic changes in their lives, to become more whole, and to re-embed themselves in the spiritual potency of Nature.

Namae is also a designer and teacher of a 3-year facilitator training curriculum, Guide of the Heart,  as well as training modules to teach facilitators how to  guide from love, and connect people to the intelligence of Life. She also manages all aspects of the non-profit, the employees and volunteers, retreats and events, the development of the organization’s website and membership program and CWays Home’s 20-acre property in Oregon.

Before CWays Home, Namae was a self-employed Guide of Conscious Ways LLC, with a private practice serving thousands of individuals and groups. She led spiritual adventure tours to Peru, Bolivia, Australia, and other locations in the States, working with indigenous healers, mystics, shamanic practitioners, spiritual guides, and teachers.

Namae graduated from the University of Technology in Sydney, Australia, with a Bachelors of Applied Science in 1980, majoring in Environmental Biology. She created a women’s landscape design company, owned and managed Sunheart Sanctuary, a holistic shamanic breath work center in the Blue Mountains outside Sydney and conducted organizational reviews as a management consultant with the Victorian and Tasmanian State Governments. In 1998, Namae heeded the call to go “walk-about”, traveling first to Hawaii and then around the world to experience and discover what it means to become a citizen of this planet, settling in the States in 2004. She has danced and taught the feminine path of tantra, lived the life of a pantheanic hermit for several years in the forests of Maui, explored the nature of consciousness and played with many artistic expressions.

Namae is deeply devoted to the awakening of Love through direct relationship with the intelligence of Life.

Dr Ashleigh Murphy-Beiner (UK) profile picture

Dr Ashleigh Murphy-Beiner (UK)

Ashleigh is a Clinical Psychologist, working with The Tavistock Trauma Service in the UK National Health Service and the Centre for Psychedelic Research at Imperial College London. As a clinician, Ashleigh specialises in the treatment of complex trauma and has worked as a therapist on Imperial’s clinical trials of psychedelic-assisted therapy. In her clinical research, Ashleigh carries out qualitative and psychotherapy process research to better understand clients and practitioners’ experiences of using psychedelic-assisted therapy to treat complex PTSD, depression and anorexia. Ashleigh has co-designed the ARC ethics framework with Dr. Meg Spriggs and colleagues to support the development of safe and ethical practice guidelines in psychedelic-assisted therapies. Ashleigh has also led a psychedelic integration group to help people access therapeutic and community-based peer support after having beneficial or challenging psychedelic experiences. Ashleigh is trained to work flexibly with psychodynamic, systemic, cognitive-behavioural and mindfulness-based therapies.

Francoise Bourzat (USA) profile picture

Francoise Bourzat (USA)

MA

Francoise Bourzat holds an MA in Somatic Psychology from New College of California (San Francisco, 1990). She was an adjunct faculty in the East West Psychology Program at the California Institute of Integral Studies from 2012 to 2016. Since 1987, Francoise has apprenticed with shamans and healers in the U.S. and Mexico. In the last 25 years, she has traveled with groups to Mexico, incorporating her counseling practice experience with her knowledge of expanded states of consciousness where she partners with Mazatec healers in Sacred Mushrooms ceremonies. She also leads workshops and contributes to conferences internationally. Her book, Consciousness Medicine is available everywhere books are sold.

Tania de Jong AM is the co-Founder and Executive Director of Mind Medicine Australia. She regularly presents on psychedelic-assisted therapies, mental health and wellbeing at major conferences and events around the world and to Governments, regulators, clinicians, philanthropists and the general public.

Tania is one of Australia’s most successful female entrepreneurs and innovators developing 6 businesses and 4 charities including Creative Universe, Creativity Australia and With One Voice, Umbrella Foundation, Creative Innovation Global, Pot-Pourri and The Song Room.

Barry Walker (USA) profile picture

Barry Walker (USA)

M.Ed., LMHC

Barry Walker is a state licensed psychotherapist in New York with over thirty years of experience. His primary focus – anxiety as the motherboard of ‘disorders’. He has a career-long interest in states of consciousness in different personality structures. He also researches the role of psychedelic substances used adjunct to psychotherapy, especially in trauma treatment.

Peter Hunt AM profile picture

Peter Hunt AM

B.Com, LL.B

As an investment banker Peter Hunt AM advised local and multi-national companies and governments in Australia for nearly 35 years.  He co-founded one of Australia’s leading investment banking advisory firms, Caliburn Partnership and was Executive Chairman of Greenhill Australia. Peter was a member of the Advisory Panel of ASIC and chaired the Vincent Fairfax Family Office.

Peter is an active philanthropist involved in funding, developing and scaling social sector organisations which seek to create a better and fairer world.  He is Chairman of Mind Medicine Australia which he established with his wife, Tania de Jong, in 2018. He regularly presents to Governments, regulators, clinicians, philanthropists and the general public on psychedelic-assisted therapies and the legal and ethical frameworks needed to ensure these treatments can be made accessible and affordable.

* Please note that faculty is subject to change based on course curriculum, availability and to ensure that overall learning experience is enhanced for the student cohort.

Course structure and contents

The course will take place over a period of 4 months with:

  • 78 hours of face-to-face or webinar-based tuition and practical instruction
  • 43 hours of additional reading, reflection and self-study expected of participants
  • Pre-course reading schedule
  • 14 online 3 hour sessions: delivered on Sundays, containing lectures with our world class faculty and practical skill development.
  • One 6-day Intensive Retreat: with primary focus on practical learning and consolidation of therapeutic skills, working with videos of real sessions, role play, feedback on skills learning and further development guidance. The residential uses breathwork to allow participants to experience an altered state based therapy and apply the clinical skills they have developed during the course.
  • Assessments: a quiz for each module, a self-reflection task, a written task and a video recorded role-play of a PAT scenario.

Core Course Content:

  • History of Psychedelic-Assisted Therapy
  • Key Concepts of Psychedelic-Assisted Therapy
  • Essentials of Pharmacology & the REBUS Theory
  • You, the Therapist
  • Ethics, Diversity & Touch
  • Screening and Preparation
  • Psilocybin-Assisted Therapy
  • MDMA-Assisted Therapy
  • Ketamine-Assisted Psychotherapy
  • Challenging Experiences & Integration
  • Trauma & Psychedelic-Assisted Therapy
  • Philosophy of Mind & Non-Materialist Perspectives
  • Regulatory Framework for Psychedelic Medicine in Australia
  • Microdosing
  • Music for Psychedelic-Assisted Therapy
  • Psychedelic-Assisted Therapy Practicum (Residential Training)

Course dates

Apply now for upcoming CPAT™ intakes:

2024 Cohort 2: July 21 – Nov 10

Sydney residential: October 21-26
Melbourne residential: October 30 – November 4

2025 Cohort 1: February 16 – June 22

Sydney residential: June 2 – 7
Melbourne residential: June 10 – 15

Testimonials

“Reflecting on the past week at the Sydney residential CPAT training with Mind Medicine Australia. Not only have I been blessed with making what I think will be lifelong friendships, but I have grown both personally and professionally beyond what I could ever have expected. Thank you! I am so excited to be at the forefront of this "renaissance" of plant medicines and truly believe that they will offer hope and a way forward to many who have felt disheartened with current mental health treatments.”

"This training not only marries scientific, Western, research-based knowledge with ancient, age-old, holistic knowledge. It puts the participant through a journey as well. Change is not only individual. It is not only in groups. It is all of the above. And more."

"This is by far the best PD course that I have ever attended! (Having attended over thirty different workshops, and PD of all sorts). To the facilitators and teachers: there are honestly not enough sufficient words to express my gratitude and appreciation to you!"

"Any self-proclaimed 'evidence based' clinician should do this course. Psychedelic medicine is here; learn about it and you will not only understand it better, but it may reinvigorate your career."

"A truly ground-breaking course on a new-old area of psychiatry. A must for anyone interested in challenging their preconceptions and offering something new to their patients. Delivered by a world class faculty and thoroughly recommend."

"The CPAT course covers all didactic material relevant to ‘psychedelic therapy’ delivered by international and Australian experts. The ‘retreat’, led by experienced facilitators, is the peak and heart of the course, giving trainees a deep, natural, transpersonal, drug-free experience of mimicking the psychedelic state."

"The MMA course was such an incredible collaboration of science and soul, mind and heart, knowledge, and gnosis. Not only were we given all the education and skills to do this work, but we were also given the deep exposure into psyche, to ensure that we do it with compassion, professionalism, and reverence. I’m so excited for the future of psychiatry thanks to MMA."

"I have found the CPAT course very educational. I feel that my understanding of the medicine has improved and the course has prepared me to both sit with patients on the medicine and to help them integrate their experiences. I would highly recommend this course to other practitioners interested in this emerging science."

"I had a great, meaningful time. It’s so rare to bring a group of people with the same interest and passion for self-growth and helping others together. This world suffers from a huge PTSD and needs this so much. Thank you."

"The course was exceptional. The content was so well put together and delivered by extremely professional presenters. Ben and Lauren were completely amazing. I felt challenged and held throughout the entire experience and the balance of ‘head’ and ‘heart’ worked very well. The breathwork was the highlight of my experience. I went into the session with a lot of anxiety but felt completely safe and held by both my sitters and the facilitator. Craig and Maurizio have an incredible presence and skill at creating a safe container. Overall, I would strongly recommend anyone thinking of doing the course to jump in and expand your mind and heart. Thank you all."

"I came to acquire knowledge about being a psychedelic therapist.. and I got that, and so much more! This was such a mind-expanding, heart-opening experience. If you are curious follow your instinct, enrol, and enjoy the journey!"

"I was sceptical initially when starting the course. I was curious as The College and TGA have made an announcement about psychedelic treatment. I am grateful for having done the course. It answered many questions and the whole experience was educational. MMA made learning fun."

Download the testimonials from our previous intakes: Download pdf (257.2 KB) Last updated: Jun 20, 2024

Course accreditation

Mind Medicine Australia’s Certificate in Psychedelic-Assisted Therapies™ is endorsed as professional development training by the organisations listed below.

It may also form the basis of individual professional development and training plans. All our training courses and events can also be used to claim ongoing Continuing Professional Development (CPD) points in Australia through professional colleges (e.g. through the Australian Psychological Society, RANZCP, RACGP…).

Please check with your professional membership body for the appropriate category and number of points.

Eligibility requirements

The CPAT™ course aims to build on skills already acquired and used by professionals working in the mental health field. The three main roles in administering PAT are the Prescriber, Primary Therapist and Secondary Therapist.

Note that this is not an entry level course that qualifies an individual to practice psychotherapy. Applicants are expected to already be qualified to practice in the mental healthcare field and have relevant clinical experience.

The CPAT™ course is available to a variety of mental healthcare professionals including:

Other relevant healthcare professionals may be considered.

Admission into the CPAT™ is dependent on several factors including potential role in PAT (prescriber, primary therapist, secondary therapist), professional qualifications, and capacity of the applicant to successfully undertake and complete the CPAT™. Preference will be given to applicants who have clinical experience in mental healthcare. Applicants must be registered with AHPRA (Australian applicants) and/or a member of a relevant professional association representing healthcare practitioners and be of good professional standing.

Note that MMA believes that to be a Primary Therapist in PAT, the practitioner should have extensive psychotherapeutic experience, preferably with significant amounts of supervision, and is/has engaged in their own self-development (eg. therapy, experience in altered states).

Applicants who do not work in one of the above professions will be considered if they:

(A) are completing study/training to work in the mental health field

OR

(B) have substantial experience in altered state based work in non-clinical environments such as breathwork practitioners, indigenous healers, shamanic practitioners.

Please note that those from the above categories will receive a certificate of participation in place of a CPAT-prescriber or CPAT-therapist certificate of completion.

Fees and payment

Application fee: $250 (non-refundable)

plus

Course fee: $10950 (by installments) or $9950 (upfront payment in full)

Please note:

Mind Medicine Australia has donated funds to The Australian National University (ANU) to enable them to conduct a study of brain activity associated with exposure to psychedelics (including MDMA and psilocybin) in people who have completed training in psychedelic assisted psychotherapy.

Payment Structure:

  • $250 application fee collected at time of application plus upfront payment in full

Then

  • One upfront payment of $9950 or 3 payments of $3650 will be issued (to be paid in full before course completion) upon acceptance into the course
  • Please note that the first payment (of either $9950 or $3650 is required to secure your place in the course)

Payment Method:

  1. The $250 application fee will be processed by PayPal. You will be taken to the PayPal site upon completion of the application form.
  2. MMA will issue your invoice(s) for remaining course fees upon acceptance into the course.

Cost of the course includes:

  • World-class program, developed in conjunction with leading international program
  • First in Australia and the Asia-Pacific region
  • Taught by international leaders and top Australian experts
  • 75 hours of live face-to-face and webinar teaching
  • Additional reading and teaching material supporting tuition
  • One weeklong residential intensive. Accommodation and meals included.
  • Residential week provides direct, personalised skill development and practical exercises, assessment and risk management skills.
  • Monitoring of skill development through on-going evaluation and coursework
  • Therapists learn skills for working in different settings: research programs, individual psychedelic therapeutic interventions within medical settings for a range of mental illness conditions, and the provision of psychological therapy and integration work outside of these settings.

CPATTM FAQs

Please read the FAQs below for Mind Medicine Australia’s (MMA) Certificate in Psychedelic-Assisted Therapies (CPAT)™. If you have further questions please contact MMA.

1. How many hours are required for the course each week?

Each week of the online course has a 3-hour class, with additional readings, experiential workshops and discussion exercises to support your learning.

We recommend allocating 6-7 hours/week to maximise the learnings and absorb the content.

2. When will I find out if I’ve been accepted into the course?

After receiving your application it will be reviewed within 3 business days. Admission interview times will be shared for applicants who meet the eligibility criteria that you can book within the following 1-2 weeks.

We review interviews at the end of each week. After you complete your admission interview you will be notified by the end of that week with an outcome. Payment in full or the first instalment will be required within 7 business days following an offer.

3. Is attendance required at all sessions?

Live attendance is not required for online sessions. We strongly encourage all students to attend as many sessions live as they can and ask questions and engage with the teachers and other students. All sessions will all be recorded for later viewing for those who cannot attend.

Attendance of the entire residential is required to complete the course.

4. What are the assessment requirements of the course?

The course has 4 assessment requirements:

  1. Module quizzes – each module has a 10-question quiz which covers the module’s learning outcomes.
  2. Self-reflection – a written self-reflective piece is completed after module 4 of the course.
  3. Written assessment – a written assessment piece is submitted at the end of the course. This assessment piece is different for prescribers and therapists. Prescribers will document a treatment protocol for either MDMA or psilocybin, and therapists will outline the therapeutic approach for a course
    of treatment.
  4. Video role play – a video role play of a preparation session is submitted at the end of the course.

5. What are the differences in the course for prescribers and therapists?

Prescribers and therapists complete the training together. All content is completed by all students.

This structure ensures that all clinicians seeking to work in PAT have a foundational understanding of all areas relevant to delivering these treatments.

Prescribers and therapists will complete different tasks in their final written assessment.

Note that prescribers who are also suitably trained to deliver therapy (such as psychiatrists) will be able to work as both a prescriber and a therapist upon completion of the course.

MMA has found that a diverse, multidisciplinary group of professionals significantly enhances the learning experience. It also leads to a strong network of life-minded professionals who often form clinical groups, networks and teams following the course.

6. Will MMA’s CPAT™ allow me to work in the PAT field?

With current regulations, Human Research Ethics Committees (HRECs) and the TGA are responsible for determining who can work as part of the multidisciplinary teams that are required to deliver psilocybin and MDMA-assisted therapy as part of the TGA’s Authorised Prescriber (AP) program.

We can confirm that MMA’s CPAT™ is being accepted by both HRECs and the TGA as suitable training to allow clinicians to work in teams delivering psilocybin and MDMA-assisted therapy.

Ketamine-assisted psychotherapy (KAP) has less regulations around who can work to deliver treatment. CPAT™ graduates will be able to deliver KAP – either by prescribing themselves or partnering with a medical doctor who can prescribe.

7. Is CPAT™ accredited?

CPAT™ is accredited for Continued Professional Development (CPD) with a number of Australian colleges and associations. These are listed on the CPAT™ website. We recommend that graduates ask their college or association to advise how many CPD points they will be credited from the CPAT™ training.

As PAT is a new and developing field, the accreditation standards and structures have not yet been in place to begin accrediting training programs. However, the training is recognised by the HRECs and the TGA. MMA is actively working with the Australian and international educational and other organisations to support further accreditation of the course as it becomes possible to do so.

Financial assistance

Financial assistance is available for our Certificate in Psychedelic-Assisted Therapies (CPAT)™!

Funding is available for outstanding practitioners in financial need and those from rural, regional areas and/or those from indigenous or other diverse groups to support part of the tuition fees for the course. Some financial assistance is available on a competitive basis.

Mind Medicine Australia group photo

How to apply

Applications open:
Are open for 2024 intakes (applicants will be considered in order of receipt. We expect the program to be over-subscribed so please register early to avoid disappointment.)

Screening and interview/finalise applicants:
Your application is processed as received and contact is made directly to assess further and arrange an interview

Application process

Step 1: Complete the Application Form, including payment of your $250 application processing fee.

Step 2: Applications will be screened, and if successful invited to an interview. These are self-scheduled via our online portal

Step 3: If successful in your interview, you will be invited to join the course. You’ll be issued a student agreement and  invoice for either $9950 upfront payment or 3 x $3650. Your place in the course will be secured upon receipt of your signed student agreement and your first payment.

Application Form

Contact us

Please use the contact form below to get in touch. Alternatively, send us an email to cpat@mindmedicineaustralia.org or give us a call: 03 8679 6015.

Name(Required)
This field is for validation purposes and should be left unchanged.

Terms and Conditions

By submitting an enrolment application for the Certificate in Psychedelic-Assisted Therapies (CPAT), you acknowledge that you have read and accepted these Terms and Conditions.

1. Enrolment

  1. A non-refundable processing fee of $250 is required for your application to proceed further.
  2. You will be required to sign a Student Code of Conduct. This is required for your application to proceed.
  3. All information contained in your application and interview process is assumed to be correct and true to the best of your knowledge. In the event that any information is discovered to be false, your right to attend the course may be forfeited.

2 Fees

  1. Prices are inclusive of GST
  2. There is an Application fee of $250 (non-refundable)
  3. The Course fee is $9000 (or $8000 upfront payment in full)
    Payment Structure:
  4. $8000 upfront payment in full
    Or
  5. $9000 paid in instalments
    1. $3000 initial payment – due with the submission of your application
    2. $3000 second instalment payment – will be invoiced separately
    3. $3000 third and final instalment payment – will be invoiced separately
  6. If your application does not progress further than the interview stage, then your course fee will be refunded.
  7. On acceptance to the course, you will be required to pay the remainder of the full course fee as per the dates on the invoice sent to you. If you require a payment plan this can be ​arranged by contacting Mind Medicine Australia prior to the invoice being sent, or within 10 business days of the invoice date.
    Where a student withdraws from study 28 days prior to commencement of a course they will receive a refund of their tuition fees paid less an administration fee of $50. There will be no refund of the application fee.
  8. Failure to make payment/s by agreed dates or failing to enter a payment plan may result in the cancellation of your enrolment without a refund, Certificates ​cannot be issued until course fees are paid in full.
  9. The course fee is derived from the following factors:
    • 90 hours of live face-to-face and webinar teaching
    • Additional reading and teaching material supporting tuition
    • Three intensives
      • one non-residential weekend in Melbourne
      • one residential weekend, accommodation and meals included
      • one-week residential, accommodation and meals included
    • Holotropic Breathwork workshop (during residential weekend): cost of Grof- trained therapist included
    • Residential week provides direct, personalised skill development and practical exercises, assessment and risk management skills.
    • Supervised practice/mentoring as required by the course*
    • Monitoring of skill development through ongoing evaluation and coursework

3. Changes to the program

  1. Mind Medicine Australia reserves the right to make changes to the program with regard to teachers, content, dates and venues should unforeseen circumstances make this necessary. Mind Medicine Australia agrees to make every effort to maintain the overall standard and integrity of the program.
  2. Mind Medicine Australia is not liable to refund the costs of the program or make any compensation in the event of force majeure, excluding travel restrictions or limitations due to the COVID-19 crisis.

4. Student Code of Conduct

  1. You are required to sign and submit the Student Code of Conduct and agree to these Terms & Conditions.

5. Attendance

  1. You agree that you will make every effort to attend all lectures/webinars, to carry out any required set tasks and/or projects.
  2. You agree that attendance of the three intensives is essential to this program and not negotiable. Failure to attend will result in non-compliance with essential program elements being recorded.
  3. You agree that attendance at these events will be at your own risk, and that Mind Medicine Australia or any staff or teachers will not be liable in the event of accident or injury.
  4. If you fail to attend and complete required tasks and/or projects you will be asked to leave the program without compensation or reimbursement.

6. Confidentiality

  1. You agree that you will keep confidential any patient or client-sensitive material which may be part of discussions, demonstrations or teaching materials presented by anyone attending the program as well as program leaders and teachers.
  2. You agree that any personal information of fellow participants arising during the program will similarly be treated as confidential.

7. Ownership and intellectual property rights

  1. All CPAT materials, whether provided online or during face-to-face intensives, are owned by Mind Medicine Australia. All intellectual property rights in all materials available from Mind Medicine Australia, including the design, graphics and text of all printed materials and the audio of all webinars and podcasts, are owned by Mind Medicine Australia. The exception is any printed or audio material not created by Mind Medicine Australia or not produced specifically as part of the program.
  2. When you are given access to the CPAT, you are granted a non-exclusive, non- transferable and revocable licence to use the materials. No CPAT content may be copied, reproduced, uploaded, posted, displayed or linked to in any way, in whole or in part, without the Mind Medicine Australia’s prior permission. Any such use is strictly prohibited and will constitute an infringement of Mind Medicine Australia’s intellectual property rights.
  3. You agree that attending any webinars will be only for yourself, and that you will not permit any person not registered to sit in on the sessions.
  4. You agree that no part of any live or web-based event in the program will be recorded or transmitted by you in any way.

8. Breaches

  1. In the event of violations of any of the terms above, an evaluation of the severity of the breach will be made by the program leaders, following which:
  2. An attempt at remediation may be discussed with you, if this is unsuccessful, a formal warning will be issued.
  3. If the breach is deemed to be serious, you will be asked to leave the program without compensation or reimbursement.

*Subject to regulatory requirements